Undisclosed GPCR Program(s)

About DJS Antibodies

DJS Antibodies is a private, pre-revenue biotech specializing in creating antibody drugs for challenging membrane protein targets, primarily GPCRs, which have historically been resistant to conventional antibody approaches. Its core technology, the HEPTAD platform, is designed to generate functional antibodies by immunizing with stabilized native target conformations. The company is advancing a pipeline of early-stage, pre-clinical programs, positioning it to address significant opportunities in immunology and oncology, though it faces typical development risks and platform validation hurdles.

Therapeutic Areas